It’s In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: Dexcom launches direct-to-watch with the G7 in the UK and Ireland, more studies looking at heart benefits with Wegovy and diabetes, a new T1D study investigating an injectable to prevent overnight hypoglycemia, lobbying for Levimir, a ChatGPT diabetes diagnosis and more!

Find out more about Moms’ Night Out 

Please visit our Sponsors & Partners – they help make the show possible!

Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (

Omnipod – Simplify Life

Learn about Dexcom 

Edgepark Medical Supplies

Check out VIVI Cap to protect your insulin from extreme temperatures

Learn more about AG1 from Athletic Greens 

Drive research that matters through the T1D Exchange

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:

Sign up for our newsletter here

Here’s where to find us:

Facebook (Group)

Facebook (Page)



Check out Stacey’s books!

Learn more about everything at our home page 

Reach out with questions or comments:

Episode transcription with sources:

Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now.


In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark


Dexcom direct to watch is live in the UK and Ireland.  First announced in 2017..  this is probably the feature most listeners have asked me to ask Dexcom about. It should be available in the US this year.. and yes.. this means direct from transmitter to watch OR transmitter to phone AND transmitter to your medical device, the G7 is the first CGM that can beam its info to three devices.

Btw, big thanks to my my friend Kamil Armacki for this news – you may know him better at Nerdabetic – he posted a video all about hit and I’ll link that up, like all of my sources, in the show notes.


New study about Wegovy – that shows the drug helped people with type 2 diabetes who also had a specific obesity-related heart condition. This condition happens when the heart pumps normally, but the organ is too stiff to fill properly.

The researchers say weight loss is a factor, but it doesn’t explain everything. Wegovy was first approved in 2021 to treat obesity. Just last month, the U.S. Food and Drug Administration also approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in obese/overweight adults with heart disease. This latest study offers up fresh evidence that Wegovy’s benefits extend to people with diabetes. I’m not sure the surprise here, because Wegovy is the exact same drug as Ozempic.. which is only approved for people with diabetes. Worth noting – Novo Nordisk funded this study – they make Ozempic and Wegovy.


Statins raise the risks for increased glucose levels and the development of type 2 diabetes among people who don’t have it but those risks are outweighed by the cardiovascular benefit, new data suggested.

Big study review of 23 trials involved more than 150-thousand people.

Moreover, they say, “since the effect of statin therapy on measures of glycemia within an individual is small, there is likely to be little clinical benefit in measuring glucose concentrations and A1c values routinely after starting statin therapy with the aim of making comparisons to values taken before the initiation of a statin. However, people should continue to be screened for diabetes and associated risk factors and have their glycemic control monitored in accordance with current clinical guidelines.”

In an accompanying editorial, Hertzel C. Gerstein, MD, and Marie Pigeyre, MD, PhD, both of McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada, noted that the decreased absolute annual incidence of life-threatening cardiovascular outcomes with statins in people at high risk for type 2 diabetes “clearly exceeds the 0.1%-1.3% per year increased absolute incidence of type 2 diabetes.”

The researchers say “these findings emphasize the importance of holistic care. As people at risk for cardiovascular outcomes are also at risk for type 2 diabetes, any prescription of a statin should be accompanied by promoting proven strategies to prevent or delay diabetes, such as modest weight reduction and increased physical activity. Finally, these findings emphasize the importance of always being alert for harmful adverse effects, even with the most beneficial and successful preventive therapies.”


New study looking for participants will investigate a new medication to help avoid nighttime low blood sugars. Right now the medication is called ZT-01 – it’s an injectable that works by increasing the amount of glucagon that is made during hypoglycemia. In a small proof-of-concept trial, 90% of participants saw increased glucagon levels after ZT-01 treatment, with no serious health events reported.

Research suggests nighttime hypoglycemia is relatively common, with a global prevalence of 73%.

You may be eligible to participate if you:

Are 18 to 75 years old and have had type 1 diabetes for at least five years

Have a history of recent nocturnal hypoglycemia

Have an A1C ≤10%

Have a BMI ≥18.5 and <33 kg/m2

People who use automated insulin delivery (AID) systems are not eligible. While this trial is not open to people with type 2 diabetes, Zucara is developing ZT-01 for both people with type 1 and with insulin-dependent type 2 diabetes, so future studies may be open to all people with diabetes.


Nearly four in every 1,000 U.S. youths and five in every 1,000 U.S. adults reported having type 1 diabetes from 2019 through 2022, according to a research letter published online April 4 in the Journal of the American Medical Association.



Michael Fang, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues updated estimates of type 1 diabetes prevalence and characterized rates in population subgroups. The analysis included data from the 2019 to 2022 cycles of the National Health Interview Survey (110,283 adults and 30,708 youths).


The researchers found that among youths, the reported prevalence of type 1 diabetes was 3.5 per 1,000, with the highest rates seen among those aged 10 to 17 years (5.0), males (4.0), Hispanic youths (3.5), and non-Hispanic White youths (3.9). The reported prevalence in adults was 5.3 per 1,000 and was highest among those aged 45 to 64 years (6.1) and 65 years and older (5.3), non-Hispanic Black adults (4.8), and non-Hispanic White adults (5.9).


“These results are consistent with the U.S. Centers for Disease Control and Prevention’s estimates for 2021,” the authors write. “This study adds to existing research by providing more precise up-to-date national estimates and by characterizing differences across subgroups.”


No update or change on Novo Nordisk’s decision to discontinue Levimir, the long acting insulin they’re taking off the market.

Alison Smart has a daughter with type 1 and says nothing else on the marked works as well for her. Smart has created the Alliance to Protect Insulin Choice, a volunteer organization and she’s lobbying congress.

She’s also reached out to Mark Cuban.. and his Cost Plus pharmacy. Cuban says he’d be happy to partner with Novo to sell Levimir. Of course, no sign that Novo is interested in partnering with anyone and so far, Cost Plus doesn’t sell insulin. But we’ll keep watching this one.

Utah mom enlists Mark Cuban in fight for daughter’s access to insulin


Becton Dickinson said on Thursday it has increased production of medical syringes in the United States after the country’s drug regulator recommended not using some China-made syringes as part of its ongoing quality probe.

The U.S.-based medical equipment maker — one of the world’s largest syringe suppliers — said it had increased manufacturing in its Nebraska and Connecticut facilities, since the U.S. Food and Drug Administration first raised concerns about China-made syringes in November.”

For more information on BD’s commitment to quality, safety and our customers, please visit:


Another non invasive CGM to talk about.. but this one’s a little different.

Biolinq has a wearable patch that uses an array of tiny electrochemical sensors to measure glucose levels from the intradermal space just below the surface of the skin. The technology combines glucose information with relative levels of activity in one device.

They say they’ll complete US U.S. pivotal clinical trials this year.

From the release: Placed on the upper forearm, the patch incorporates an intuitive display on the device. It informs users when glucose levels stand within a target range and when they go beyond a healthy range. The company designed its sensors on a silicon chip for redundancy, reliability and multi-analyte capabilities.


“Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Rich Yang, CEO, Biolinq. “Over the past decade, our team has been pioneering a new biosensor platform designed to inform and inspire, with a mission to reach more people that are in need of simple solutions to improve metabolic health.”

Biolinq raises $58M to support intradermal glucose sensor




I’m sure this isn’t the first or only time it’s happened, but a South Carolina man used ChatGPT to get the correct diabetes diagnosis. Cooper Myers had been diagnosed with type 1 – his father, grandfather and great grandfather all had type 2 but they were all rally lean, he says almost underweight.

Then in January 2023, Myers consulted the artificial intelligence program ChatGPT and asked: “If my father is a skinny type 2. My grandfather is a skinny Type 2 and I am a skinny Type 1 with no antibodies, then could we have a different kind of diabetes?”

ChatGPT came back with a list of diabetes conditions that were not the common Type 1 or Type 2 and a little about each of them. One of them was MODY: Maturity-Onset Diabetes of the Young. It happens when there is a gene mutation through many generations. It also resembles Type 1 or Type 2.

He went to a doctor – didn’t say anything about ChatGPT just pushed for another diabetes diagnosis and found out he has the gene mutation for MODY 2, one of the three kinds of MODY. His gene was 90% affected, which meant that while he did produce some insulin, it wasn’t enough.

MODY is treated very differently – he can take oral meds twice a day – bit difference from an insulin pump.

Leave a Reply